Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

Leukemia & Lymphoma
Pier Paolo PiccalugaMichele Baccarani

Abstract

Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly patients with acute myeloid leukemia (AML) in relapse. Nevertheless, no data are until now available concerning the possible efficacy of GO for myeloid sarcomas (MS). We treated with GO 24 AML patients, in 5 cases presenting with myeloid sarcomas of the skin or bones. The overall complete response rate was 21%. The median duration of response was 6 months. Four out of the 5 patients with myeloid sarcoma showed a regression of the masses, in two cases also obtaining a clearance of marrow blasts. The most common adverse events included thrombocytopenia, neutropenia, infections, elevation of bilirubin and hepatic transaminases. Notably, severe bleeding occurred in 5 cases (21%). VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding.

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Mar 16, 2002·Blood·Pankaj RajvanshiGeorge B McDonald
Oct 12, 2002·American Journal of Clinical Pathology·Iman JilaniMaher Albitar
Aug 27, 2003·Seminars in Oncology·Marcie R Tomblyn, Martin S Tallman

❮ Previous
Next ❯

Citations

May 1, 2007·Current Hematologic Malignancy Reports·István Molnár, Bayard L Powell
Jul 28, 2007·Nature Clinical Practice. Oncology·Taofeek OwonikokoAnastasios Raptis
Feb 9, 2010·The Tohoku Journal of Experimental Medicine·Toshihiko AndoYukio Tanizawa
Dec 3, 2013·International Journal of Hematology·Hiroko TsunemineTakayuki Takahashi
Jun 9, 2009·Clinical Interventions in Aging·Hien K Duong, Mikkael A Sekeres
May 28, 2013·International Journal of Hematology·Akihiro Takeshita
May 29, 2014·Expert Opinion on Biological Therapy·Felicitas Thol, Richard F Schlenk
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Jun 1, 2008·Expert Opinion on Drug Discovery·Hideo UchidaMasahiro Kizaki
Aug 4, 2011·Expert Opinion on Biological Therapy·Marie-Luise Hütter, Richard F Schlenk
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Jan 18, 2006·British Journal of Haematology·Apostolia-Maria TsimberidouHagop M Kantarjian
Oct 1, 2011·Therapeutic Advances in Hematology·Batia Avni, Maya Koren-Michowitz
Jun 17, 2020·The Journal of Spinal Cord Medicine·Shiyuan HanJun Gao
Jul 15, 2017·Internal Medicine Journal·Andrea PiccinSimone Cesaro
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejandro D Ricart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.